Bio-Rad Laboratories, Inc. Class A Common Stock vs Expensify Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Expensify Inc trades at $2.34 (market cap $209.73M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 45× Expensify Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Expensify Inc nearer its low. Which is the better fit depends on your goals.
| BIO | EXFY | |
|---|---|---|
Market Cap | $9.43B | $209.73M |
Sector | Health | Technology |
52-Week High | $356.25 | $2.69 |
52-Week Low | $241.71 | $0.75 |
Enterprise Value | $9.18B | $149.35M |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →